Official Title: A phase II study of pembrolizumab and eribulin in patients with HRpositive/HER2-negative metastatic breast cancer previously treated with anthracyclines and taxanes.
This a multicenter, open-label, phase II clinical trial to assess the efficacy of pembrolizumab in combination with eribulin in female patients older than 18 years old with hormone receptor-(HR)positive/HER2-negative metastatic breast cancer (MBC) previously treated with at least one, but not more than two, prior chemotherapeutic regimens for treatment of locally recurrent and/or metastatic disease. Prior therapy must have included an anthracycline and a taxane. Prior anti-hormonal therapy in the metastatic disease setting is mandatory.
The number of patients to be included is 44 patients at 11 sites. All eligible patients will be treated with MK3475 (pembrolizumab) 200 mg on day 1 of each 21-day cycle and eribulin 1.23 mg/m2 (equivalent to eribulin mesylate at 1.4 mg/m2) on days 1 and 8 of every 21-day cycle.
KELLY at clinicaltrials.gov
SABCS 2019 Kelly Poster – List of COIs
SABCS 2019 Poster